Federated Hermes, Inc. Verve Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 7,859 shares of VERV stock, worth $44,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,859

Previous 1,151,550 99.32%

Holding current value

$44,088

Previous $5.62 Million 99.32%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$4.4 - $7.86 $5.03 Million - $8.99 Million	-1,143,691 Reduced 99.32%	7,859 $38,000
Q2 2024 Aug 08, 2024	SELL	$4.76 - $12.79 $11.4 Million - $30.8 Million	-2,405,027 Reduced 67.62%	1,151,550 $5.62 Million
Q1 2024 May 14, 2024	SELL	$10.81 - $17.96 $4.58 Million - $7.61 Million	-423,795 Reduced 10.65%	3,556,577 $47.2 Million
Q4 2023 Jan 31, 2024	BUY	$8.84 - $18.7 $12.8 Million - $27.1 Million	1,448,003 Added 57.18%	3,980,372 $55.5 Million
Q3 2023 Nov 13, 2023	BUY	$11.42 - $20.82 $1.48 Million - $2.7 Million	129,729 Added 5.4%	2,532,369 $33.6 Million
Q1 2023 May 08, 2023	BUY	$14.3 - $24.01 $4.64 Million - $7.79 Million	324,351 Added 15.61%	2,402,640 $34.6 Million
Q4 2022 Feb 13, 2023	BUY	$17.85 - $40.7 $5.86 Million - $13.4 Million	328,552 Added 18.78%	2,078,289 $40.2 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $10.2 Million - $27 Million	651,900 Added 59.38%	1,749,737 $60.1 Million
Q2 2022 Aug 15, 2022	BUY	$11.14 - $23.17 $4.32 Million - $8.98 Million	387,600 Added 54.57%	1,097,837 $16.8 Million
Q1 2022 May 13, 2022	BUY	$20.92 - $39.36 $7.12 Million - $13.4 Million	340,237 Added 91.96%	710,237 $16.2 Million
Q2 2021 Aug 16, 2021	BUY	$31.92 - $60.25 $11.8 Million - $22.3 Million	370,000 New	370,000 $22.3 Million

Others Institutions Holding VERV

# of Institutions

186

Shares Held

73.3M

Call Options Held

85K

Put Options Held

215K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $336M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Verve Therapeutics, Inc. Transaction History